Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

Allogene Therapeutics

Status: Invitation-only

Conditions: Solid Tumors; Hematologic Malignancies

Study type: Observational

Funder types: Industry

Identifiers

NCT06925685

ALLO-LTFU-101

Details and patient eligibility

About

An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study. Participants will be followed for 15 years after their last infusion of an allogenic CAR T cell product.

Enrollment: 50 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Received an allogenic CAR T-cell product infusion to treat an oncologic condition in a previous Allogene or Servier sponsored clinical study

Exclusion criteria

• Less than 12 months of follow up after the last allogeneic CAR T-cell product, unless approved by the Allogene Medical Monitor